Galanin receptor 1 deletion exacerbates hippocampal neuronal loss after systemic kainate administration in mice

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Elyse Schauwecker, Paula ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALANIN; GALANIN RECEPTOR 1; KAINIC ACID; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CELL LOSS; CONTROLLED STUDY; DENTATE HILUS; DISEASE PREDISPOSITION; GENOTYPE; HIPPOCAMPUS; MALE; MOUSE; NERVE CELL; NERVE CELL DEGENERATION; NERVE CELL LESION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEIZURE;

ANIMALS; GALANIN; GENE DELETION; GENOTYPE; HIPPOCAMPUS; KAINIC ACID; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; NEUROPEPTIDES; RECEPTOR, GALANIN, TYPE 1; RNA, MESSENGER; STATUS EPILEPTICUS;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 78650774005     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015657     Document Type: Article

References (69)

1. Babb TL, Brown WJ (1986) Neuronal, dendritic, and vascular profiles of human temporal lobe epilepsy correlated with cellular physiology in vivo. Adv Neurol 44: 949-966.
2. Wolf HK, Campos MG, Zentner J, Hufnagel A, Schramm J, et al. (1993) Surgical pathology of temporal lobe epilepsy. Experience with 216 cases. J Neuropathol Exp Neurol 52: 499-506.
3. Engel J, Jr., Babb TL, Crandall PH (1989) Surgical treatment of epilepsy: opportunities for research into basic mechanisms of human brain function. Arch Neurochir Suppl 46: 3-8.
4. Blümcke I, Suter B, Behle K, Kuhn R, Schramm J, et al. (2000) Loss of hilar mossy cells in Ammon's horn sclerosis. Epilepsia 41(Suppl6): S174-S180.
5. Berkovic SF, Mulley JC, Scheffer IE, Petrou S (2006) Human epilepsies: interaction of genetic and acquired factors. Trends Neurosci 29: 391-397.
6. Tan NC, Mulley JC, Scheffer IE (2006) Genetic dissection of the common epilepsies. Curr Opin Neurol 19: 157-163.
7. Rothman SM, Olney JW (1986) Glutamate and the patho-physiology of hypoxic-ischemic brain damage. Ann Neurol 19: 105-111.
8. Choi DW (1988a) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623-634.
9. Choi DW (1988b) Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci 11: 465-469.
10. Meldrum B, Garthwaite J (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 11: 379-387.
11. Beal MF (1992) Mechanisms of excitotoxicity in neurologic diseases. FASEB J 6: 3388-3344.
12. Lipton SA, Rosenberg PA (1994) Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330: 613-622.
13. Mattson MP, Mark RJ (1996) Excitotoxicity and excitoprotection in vitro. Adv Neurol 71: 1-30.
14. Doble A (1999) The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 81: 163-221.
15. Upton N, Stratton S (2003) Recent developments from genetic mouse models of seizures. Curr Opin Pharmacol 3: 19-26.
16. Santos JB, Schauwecker PE (2003) Protection provided by cyclosporin A against excitotoxic neuronal death is genotype dependent. Epilepsia 44: 995-1002.
17. Schauwecker PE, Steward O (1997) Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. Proc Natl Acad Sci USA 94: 4103-4108.
18. Schauwecker PE, Ramirez JJ, Steward O (2000) Genetic dissection of the signals that induce synaptic reorganization. Exp Neurol 161: 139-152.
19. Schauwecker PE, Williams RW, Santos JB (2004) Genetic control of sensitivity to hippocampal cell death induced by kainic acid: a quantitative trait loci analysis. J Comp Neurol 477: 96-107.
20. Lorenzana A, Chancer Z, Schauwecker PE (2007) A quantitative trait locus on chromosome 18 is a critical determinant of excitotoxic cell death susceptibility. Eur J Neurosci 25: 1998-2008.
21. Kong S, Lorenzana A, Deng Q, McNeill TH, Schauwecker PE (2008) Variation in Galr1 expression determines susceptibility to excitotoxin-induced cell death in mice. Genes, Brain & Behav 7: 587-598.
22. Antonelli T, Tomasini MC, Finetti S, Giardino L, Calzà L, et al. (2002) Neurotensin enhances glutamate excitotoxicity in mesencephalic neurons in primary culture. J Neurosci Res 70: 766-773.
23. Silva AP, Carvalho AP, Malva JO (2003) Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus. Neuropharmacology 44: 289-292.
24. Jayakar SS, Dikshit M (2004) AMPA receptor regulation mechanisms: future target for safer neuroprotective drugs. Int J Neurosci 114: 695-734.
25. Crawley JN (1996) Minireview. Galanin-acetylcholine interactions: Relevance to memory and Alzheimer's disease. Life Sci 58: 2185-2199.
26. Ogren SO, Kuteeva E, Hökfelt T, Kehr J (2006) Galanin receptor antagonists: A potential novel pharmacological treatment for mood disorders. CNS Drugs 20: 633-654.
27. Lu X, Sharkey L, Bartfai T (2007) The brain galanin receptors: Targets for novel antidepressant drugs. CNS Neurol Disord Drug Targets 6: 183-192.
28. Wiesenfelt-Hallin Z, Xu XJ (2001) Neuropeptides in neuropathic and inflammatory pain with special emphasis on cholecystokinin and galanin. Eur J Pharmacol 429: 49-59.
29. Liu HX, Hökfelt T (2002) The participation of galanin in pain processing at the spinal level. Trends Pharmacol Sci 23: 468-474.
30. Kalra SP, Horvath TL (1998) Neuroendocrine interactions between galanin, opioids, and neuropeptide y in the control of reproduction and appetite. Ann NY Acad Sci 863: 236-240.
31. Leibowitz SF (2005) Regulation and effects of hypothalamic galanin: Relation to dietary fat, alcohol ingestion, circulating lipids and energy homeostasis. Neuropeptides 39: 327-332.
32. Holmes FE, Mahoney S, King VR, Bacon A, Kerr NCH, et al. (2000) Targeted disruption of the galanin gene reduces the number of sensory neurons and their regenerative capacity. Proc Natl Acad Sci USA 97: 11563-11568.
33. O'Meara G, Coumis U, Ma SY, Kehr J, Mahoney S, et al. (2000) Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons. Proc Natl Acad Sci USA 97: 11569-11574.
34. Mahoney SA, Hosking R, Farrant S, Holmes FE, Jacoby AS, et al. (2003) The second galanin receptor GalR2 plays a key role in neurite outgrowth from adult sensory neurons. J Neurosci 23: 416-421.
35. Elliott-Hunt CR, Marsh B, Bacon A, Pope R, Vanderplank P, et al. (2004) Galanin acts as a neuroprotective factor to the hippocampus. Proc Natl Acad Sci USA 101: 5105-5110.
36. Elliott-Hunt CR, Pope RJP, Vanderplank P, Wynick D (2007) Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. J Neurochem 100: 780-789.
37. Iismaa TP, Shine J (1999) Galanin and galanin receptors. Results Probl Cell Differ 26: 257-291.
38. Branchek TA, Smith KE, Gerald C, Walker MW (2000) Galanin receptor subtypes. Trends Pharmacol Sci 21: 109-117.
39. Lang R, Gundlach AL, Kofler B (2007) The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 115: 177-207.
40. Mazarati A, Lu X (2005) Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors. Neuropeptides 39: 277-280.
41. Mazarati AM, Sollenberg U, Lundström L, Shin D, Langel U, et al. (2006) Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: the effects of subtype selective agonists and the role of G-protein mediated signaling. J Pharmacol Exp Ther 318: 700-708.
42. Mazarati A, Lu X, Shinmey S, Badie-Mahdavi H, Bartfai T (2004) Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice. Neuroscience 128: 431-441.
43. Haberman RP, Samulski RJ, McCown TJ (2003) Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med 9: 1076-1080.
44. Ben-Ari Y (1990) Galanin and gilbenclamide modulate the anoxic release of glutamate in rat CA3 hippocampal neurons. Eur J Neurosci 2: 62-68.
45. Olney JW, Fuller T, de Gubareff T (1979) Acute dendrotoxic changes in the hippocampus of kainate treated rats. Brain Res 176: 91-100.
46. Ben-Ari Y, Tremblay E, Riche D, Ghilini G, Naquet R (1981) Electrographic, clinical and pathological alterations following systemic administration of kainic acid, bicuculline or pentetrazole: metabolic mapping using the deoxyglucose method with special reference to the pathology of epilepsy. Neuroscience 6: 1361-1391.
47. Lothman EW, Collins RC (1981) Kainic acid induced limbic seizures: metabolic, behavioral, electroencephalographic and neuropathological correlates. Brain Res 218: 299-318.
48. Coyle JT (1983) Neurotoxic action of kainic acid. J Neurochem 41: 1-11.
49. Sperk G, Lassmann H, Baran H, Kish SJ, Seitelberger F, et al. (1983) Kainic acid induced seizures: neurochemical and histopathological changes. Neuroscience 10: 1301-1315.
50. Ben-Ari Y, Cossart R (2000) Kainate, a double agent that generates seizures: two decades of progress. Trends Neurosci 23: 580-587.
51. Schwob JE, Fuller T, Price JL, Olney JW (1980) Widespreaad patterns of neuronal damage following systemic or intracerebral injections of kainic acid: a histological study. Neuroscience 9: 991-1014.
52. Nadler JV, Cuthbertson GJ (1980) Kainic acid neurotoxicity toward hippocampal formation: dependence on specific excitatory pathways. Brain Res 195: 47-56.
53. Nadler JV, Perry BW, Gentry C, Cotman CW (1980) Degeneration of hippocampal CA3 pyramidal cells induced by intraventricular kainic acid. J Comp Neurol 192: 333-359.
54. Ben-Ari Y, Tremblay E, Berger M, Nitecka L (1984) Kainic acid seizure syndrome and binding sites in developing rats. Brain Res 316: 284-288.
55. McLin, JP, Steward O (2006) Comparison of seizure phenotype and neurodegeneration induced by systemic kainic acid in inbred, outbred, and hybrid mouse strains. Eur J Neurosci 24: 2191-202.
56. Mazarati AM, Hohmann JG, Bacon A, Liu H, Sankar R, et al. (2000) Modulation of hippocampal excitability and seizures by galanin. J Neurosci 20: 6276-6281.
57. Hwang IK, Yoo KY, Kim DS, Do SG, Oh YS, et al. (2004) Expression and changes of galanin in neurons and microglia in the hippocampus after transient forebrain ischemia in gerbils. Brain Res 1023: 193-199.
58. Pirondi S, Fernandez M, Schmidt R, Hökfelt T, Giardino L, et al. (2005) The galanin-R2 agonist AR-M1896 reduces glutamate toxicity in primary neural hippocampal cells. J Neurochem 95: 821-833.
59. Kokaia M, Holmberg K, Nanobashvili A, Xu ZQ, Kokaia Z, et al. (2001) Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin. Proc Natl Acad Sci USA 98: 14006-14011.
60. Jacoby AS, Hort YJ, Constantinescu G, Shine J, Iismaa TP (2002) Critical role for GALR1 galanin receptor in galanin regulation of neuroendocrine function and seizure activity. Mol Brain Res 107: 195-200.
61. Jungnickel SR, Gundlach AL (2005) [125I]-Galanin binding in brain of wildtype, and galanin-and GalR1-knockout mice: strain and species differences in GalR1 density and distribution. Neuroscience 131: 407-421.
62. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 16: 1215.
63. Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386.
64. Franklin KBJ, Paxinos G (1997) The Mouse Brain in Stereotaxic Coordinates. New York: Academic Press.
65. Racine RJ (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 32: 281-294.
66. Ben-Ari Y (1985) Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 14: 375-403.
67. Sperk G (1994) Kainic acid seizures in the rat. Prog Neurobiol 42: 1-32.
68. Nadler JV, Evenson DA (1983) Use of excitatory amino acids to make axonsparing lesions of hypothalamus. Methods Enzymol 103: 393-400.
69. Sidman RL, Angevine JB, Taber Pierce E (1971) Atlas of the Mouse Brain and Spinal Cord. Cambridge: Harvard University Press.